

Reference:	FOI.12674.23
Subject:	Intra-vitreous injections or implants
Date of Request:	15 September 2023

Requested:

Could you please tell me how many of the following intra-vitreous injections/implants has your trust administered in the four-month period from May to August 2023:

- Aflibercept
- Bevacizumab - Avastin
- Bevacizumab - Biosimilar
- Brolucizumab
- Dexamethasone
- Faricimab
- Fluocinolone acetonide
- Ranibizumab - Lucentis (pre-filled syringes)
- Ranibizumab - Lucentis (vials)
- Ranibizumab - Ongavia

Response:

Hywel Dda University Health Board (UHB) provides, within the table below, the number of intra-vitreous injections/implants administered, for the medications listed, during the period 1 May to 31 August 2023.

	Number
Aflibercept	2,172
Bevacizumab - Avastin	0
Bevacizumab - Biosimilar	0
Brolucizumab	*
Dexamethasone	39
Faricimab	7
Fluocinolone acetonide	0
Ranibizumab - Lucentis (pre-filled syringes)	331
Ranibizumab - Lucentis (vials)	0
Ranibizumab - Ongavia	1,151

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low number of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.